251 related articles for article (PubMed ID: 31448227)
1. PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
Pernas S; Petit A; Climent F; Paré L; Perez-Martin J; Ventura L; Bergamino M; Galván P; Falo C; Morilla I; Fernandez-Ortega A; Stradella A; Rey M; Garcia-Tejedor A; Gil-Gil M; Prat A
Front Oncol; 2019; 9():707. PubMed ID: 31448227
[No Abstract] [Full Text] [Related]
2. Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Díaz-Redondo T; Lavado-Valenzuela R; Jimenez B; Pascual T; Gálvez F; Falcón A; Alamo MDC; Morales C; Amerigo M; Pascual J; Sanchez-Muñoz A; González-Guerrero M; Vicioso L; Laborda A; Ortega MV; Perez L; Fernandez-Martinez A; Chic N; Jerez JM; Alvarez M; Prat A; Ribelles N; Alba E
Front Oncol; 2019; 9():1178. PubMed ID: 31750258
[No Abstract] [Full Text] [Related]
3. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.
Prat A; Bianchini G; Thomas M; Belousov A; Cheang MC; Koehler A; Gómez P; Semiglazov V; Eiermann W; Tjulandin S; Byakhow M; Bermejo B; Zambetti M; Vazquez F; Gianni L; Baselga J
Clin Cancer Res; 2014 Jan; 20(2):511-21. PubMed ID: 24443618
[TBL] [Abstract][Full Text] [Related]
4. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.
Dieci MV; Prat A; Tagliafico E; Paré L; Ficarra G; Bisagni G; Piacentini F; Generali DG; Conte P; Guarneri V
Ann Oncol; 2016 Oct; 27(10):1867-73. PubMed ID: 27484801
[TBL] [Abstract][Full Text] [Related]
5. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
6. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Llombart-Cussac A; Cortés J; Paré L; Galván P; Bermejo B; Martínez N; Vidal M; Pernas S; López R; Muñoz M; Nuciforo P; Morales S; Oliveira M; de la Peña L; Peláez A; Prat A
Lancet Oncol; 2017 Apr; 18(4):545-554. PubMed ID: 28238593
[TBL] [Abstract][Full Text] [Related]
7. Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
Pernas S; Petit A; Climent F; Paré L; Perez-Martin J; Ventura L; Bergamino M; Galván P; Falo C; Morilla I; Fernandez-Ortega A; Stradella A; Rey M; Garcia-Tejedor A; Gil-Gil M; Prat A
Front Oncol; 2019; 9():967. PubMed ID: 31598491
[TBL] [Abstract][Full Text] [Related]
8. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis.
Schettini F; Pascual T; Conte B; Chic N; Brasó-Maristany F; Galván P; Martínez O; Adamo B; Vidal M; Muñoz M; Fernández-Martinez A; Rognoni C; Griguolo G; Guarneri V; Conte PF; Locci M; Brase JC; Gonzalez-Farre B; Villagrasa P; De Placido S; Schiff R; Veeraraghavan J; Rimawi MF; Osborne CK; Pernas S; Perou CM; Carey LA; Prat A
Cancer Treat Rev; 2020 Mar; 84():101965. PubMed ID: 32000054
[TBL] [Abstract][Full Text] [Related]
9. Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination.
Swain SM; Tang G; Lucas PC; Robidoux A; Goerlitz D; Harris BT; Bandos H; Geyer CE; Rastogi P; Mamounas EP; Wolmark N
Breast Cancer Res Treat; 2019 Nov; 178(2):389-399. PubMed ID: 31428908
[TBL] [Abstract][Full Text] [Related]
10. Dynamic changes in intrinsic subtype, immunity status, and risk score before and after neoadjuvant chemo- and HER2-targeted therapy without pCR in HER2-positive breast cancers: A cross-sectional analysis.
Chen P; Mao X; Ma N; Wang C; Yao G; Ye G; Zhou D
Medicine (Baltimore); 2022 Aug; 101(31):e29877. PubMed ID: 35945759
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy.
Shi Z; Liu Y; Zhang S; Cai S; Liu X; Meng J; Zhang J
Discov Oncol; 2023 Apr; 14(1):49. PubMed ID: 37099044
[TBL] [Abstract][Full Text] [Related]
12. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
Ohara AM; Naoi Y; Shimazu K; Kagara N; Shimoda M; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Feb; 173(3):533-543. PubMed ID: 30361874
[TBL] [Abstract][Full Text] [Related]
13. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.
Prat A; Fan C; Fernández A; Hoadley KA; Martinello R; Vidal M; Viladot M; Pineda E; Arance A; Muñoz M; Paré L; Cheang MC; Adamo B; Perou CM
BMC Med; 2015 Dec; 13():303. PubMed ID: 26684470
[TBL] [Abstract][Full Text] [Related]
14. PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study.
Wang L; Li Q; Aushev VN; Neugut AI; Santella RM; Teitelbaum S; Chen J
Breast Cancer; 2021 Nov; 28(6):1235-1242. PubMed ID: 34003448
[TBL] [Abstract][Full Text] [Related]
15. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.
Ohzawa H; Sakatani T; Niki T; Yasuda Y; Hozumi Y
Breast Cancer; 2014 Sep; 21(5):563-70. PubMed ID: 23108629
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial.
Perez EA; Ballman KV; Mashadi-Hossein A; Tenner KS; Kachergus JM; Norton N; Necela BM; Carr JM; Ferree S; Perou CM; Baehner F; Cheang MC; Thompson EA
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27794124
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of the intrinsic molecular subtypes of breast cancer.
Prat A; Pineda E; Adamo B; Galván P; Fernández A; Gaba L; Díez M; Viladot M; Arance A; Muñoz M
Breast; 2015 Nov; 24 Suppl 2():S26-35. PubMed ID: 26253814
[TBL] [Abstract][Full Text] [Related]
18. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Pascual T; Martin M; Fernández-Martínez A; Paré L; Alba E; Rodríguez-Lescure Á; Perrone G; Cortés J; Morales S; Lluch A; Urruticoechea A; González-Farré B; Galván P; Jares P; Rodriguez A; Chic N; Righi D; Cejalvo JM; Tonini G; Adamo B; Vidal M; Villagrasa P; Muñoz M; Prat A
Front Oncol; 2019; 9():303. PubMed ID: 31106144
[No Abstract] [Full Text] [Related]
19. NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2
Jacobs SA; Robidoux A; Abraham J; Pérez-Garcia JM; La Verde N; Orcutt JM; Cazzaniga ME; Piette F; Antolín S; Aguirre E; Cortes J; Llombart-Cussac A; Di Cosimo S; Kim RS; Feng H; Lipchik C; Lucas PC; Srinivasan A; Wang Y; Song N; Gavin PG; Balousek AD; Paik S; Allegra CJ; Wolmark N; Pogue-Geile KL
Breast Cancer Res; 2019 Dec; 21(1):133. PubMed ID: 31796073
[TBL] [Abstract][Full Text] [Related]
20. Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer.
Abdel-Razeq H; Khalil H; Assi HI; Dargham TB
Curr Oncol; 2022 Aug; 29(8):5810-5822. PubMed ID: 36005196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
